TP53 and non-small cell lung carcinoma: About 10% of the patients had KRAS+/TP53+ NSCLC, whereas 18%, 36%, and 36% had KRAS+/TP53-, KRAS-/TP53+, and KRAS-/TP53- NSCLC, respectively.